Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
about
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersDynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cellsMore than markers: biological significance of cancer stem cell-defining molecules.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyMotesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporterNeratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoproteinDasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivoRhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft modelsEffect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Reversing multidrug resistance by tyrosine kinase inhibitorsPharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoTyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.Human ABCG2: structure, function, and its role in multidrug resistance.Resistance to antiangiogenic therapies.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.ABCG2/BCRP: Specific and Nonspecific Modulators.Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function.Euphorbia factor L1 reverses ABCB1-mediated multidrug resistance involving interaction with ABCB1 independent of ABCB1 downregualtion.ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.Role of ABC transporters in cancer chemotherapy.
P2860
Q24617999-4A361280-8E11-4B8E-B184-F375E9849BF0Q28476445-333787CE-7FC2-4918-A34B-A790DCD73FD2Q33661278-36591CEA-A9AA-43AC-AAF3-FBE546AB8C0DQ33828409-F0FABFF8-B40A-40BB-9894-E0E9B581EC0CQ34046157-3AF81312-2442-439F-A6CE-FB1FF3BF1615Q34253081-9819BEE5-3650-4ED3-A8FE-9172487A2164Q34567910-E3A4C348-44BC-491E-9F00-3799827442DEQ34795914-83CA5974-2972-4457-94FE-2DCF9FDC7E91Q35171274-C0BC99DB-3238-43AD-9D94-766A56B5FF5CQ35708124-6E7115B5-C33F-422F-96F7-1E2946FE556BQ35763457-24682BE9-82DB-4D41-A9CD-20FC9554CB1EQ35946822-F8182B89-598E-4876-8575-B11C7AC567C8Q36021057-C8041452-0B20-475B-820E-D98D08AA41ECQ36057369-8EDE82EC-1DEE-41CE-B1D3-432AEDFCB772Q36166672-B882D510-4624-4B8F-9253-EF744AFB89EEQ36212765-DBEE1C9E-084D-4776-86CA-153414501E4AQ36282183-0894A12E-5F81-4CFD-820D-9AD2020D6A7BQ36308299-92F2FB30-C4B4-40F2-AFDC-EF29EB452EA4Q36442931-A3FE7F85-9F53-4302-AF1B-5BAE714A918EQ36689070-AFFFF85A-EF4F-40D2-820A-E2FAE8ED481BQ37183670-56831315-3D3E-4E27-8365-555A206BF3B8Q37331814-0E106507-72C0-47C7-B883-B0B90679825DQ37333659-48277554-F569-49F7-A656-D39460923EE0Q37739472-B7C99A42-58C5-4712-A404-C3C6F4BBF23DQ37853578-9A64B7F1-77F0-4456-ABFF-2FF355AC0253Q37937579-A3E4CF67-C03A-43E1-AE9E-71047DB129D5Q38003156-7E818BCD-EE2C-4F4B-A858-30221B48EC7BQ38232852-66BB07D5-A767-46BA-92F8-15ECA7114F83Q38246305-35BCAC67-F32C-4B37-9E3A-A8D86DA08A34Q38812851-6BD1686E-BBC7-437F-A84B-0BE616FA90DCQ38848383-4A24A93B-2CA0-43D1-840C-9A927248EC60Q39013427-EE8FE8FC-ACA9-4EDE-9A06-1CEFAE766563Q39015818-C96571DB-622D-4B28-AF46-40B761139289Q39049159-5350C074-91F2-44BA-93CC-547046813B79Q39183426-AAA4D20E-AD00-406D-8F7C-2A339F9818CBQ39594943-BFC8B521-0DE9-44AB-A73D-8E166EC419C1Q40852245-FF437137-53FE-435B-970E-965A8F4CF29EQ41813347-7667BEC7-6D06-4A8B-B59F-248A887201ACQ41872813-BFE076CD-2A29-4601-A190-6B682D647553Q42637698-993A899E-F73C-4E99-A00D-3839ACD9F5AD
P2860
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@en
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@nl
type
label
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@en
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@nl
prefLabel
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@en
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@nl
P2093
P1433
P1476
Sensitization of ABCG2-overexp ...... ibiting the function of ABCG2.
@en
P2093
Amit K Tiwari
Chun-ling Dai
Xiu-zhen Tong
Yan-sheng Wang
Yan-yan Yan
Yong-ju Liang
Zhe-sheng Chen
P356
10.1016/J.CANLET.2009.01.027
P407
P577
2009-02-18T00:00:00Z